Table 1 Case series characteristics and EGFR mutations distribution
N | EGFR mutations | ||||
|---|---|---|---|---|---|
Total mutated | p value | EXON 19 | EXON 21 | ||
Total | 321 | 61 (19.0%) | 44 (72.1%) | 17 (27.9%) | |
Sex | |||||
Male | 186 (57.9%) | 21 (11.3%) | <0.0001 | 14 (66.7%) | 7 (33.3%) |
Female | 135 (42.1%) | 40 (29.6%) | 30 (75.0%) | 10 (25.0%) | |
Surgical samples | 75 (23.4%) | 17 (22.6%) | 0.40 | 10 (58.8%) | 7 (41.2%) |
Non surgical samples | 246 (76.6%) | 44 (17.8%) | 34 (77.2%) | 10 (22.7%) | |
Biopsies | 150 (46.7%) | 26 (17.3%) | 0.86 | 20 (76.9%) | 6 (23.1%) |
Cytology (cell blocks) | 87 (27.1%) | 16 (18.3%) | 14 (87.5%) | 2 (12.5%) | |
Cytology (smears) | 9 (2.8%) | 2 (22.2%) | 0 | 2 (100%) | |
Location | |||||
Primary tumors | 226 (70.4%) | 45 (19.9%) | 0.64 | 33 (73.3%) | 12 (26.7%) |
Metastases | 95 (29.6%) | 16 (16.8%) | 11 (68.8%) | 5 (31.2%) | |
Diagnosis | |||||
ADC | 269 (83.8%) | 53 (19.7%) | 0.83 | 37 (69.8%) | 16 (30.2%) |
NSCLC (favor ADC) | 37 (11.6%) | 7 (18.9%) | 7 (100%) | 0 (0%) | |
NSCLC NOS | 4 (1.2%) | 0 | - | - | |
Non-ADC | 11 (3.4%) | 1 (9.1%) | 0 (0%) | 1 (100%) | |